Silvia Pietrobono, Eugenio Gaudio, Sinforosa Gagliardi, Mariapaola Zitani, Laura Carrassa, Francesca Migliorini, Elena Petricci, Fabrizio Manetti, Nikolai Makukhin, Adam G Bond, Brooke D Paradise, Alessio Ciulli, Martin E Fernandez-Zapico, Francesco Bertoni, Barbara Stecca
Despite the development of new targeted and immune therapies, the prognosis of metastatic melanoma remains bleak. Therefore, it is critical to better understand the mechanisms controlling advanced melanoma to develop more effective treatment regimens. Hedgehog/GLI (HH/GLI) signaling inhibitors targeting the central pathway transducer Smoothened (SMO) have shown to be clinical efficacious in skin cancer; however, several mechanisms of non-canonical HH/GLI pathway activation limit their efficacy. Here, we identify a novel SOX2-BRD4 transcriptional complex driving the expression of GLI1, the final effector of the HH/GLI pathway, providing a novel mechanism of non-canonical SMO-independent activation of HH/GLI signaling in melanoma...
May 6, 2021: Oncogene